HAVN Life Sciences (OTCMKTS:HAVLF – Get Free Report) and EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.
This is a breakdown of current ratings and recommmendations for HAVN Life Sciences and EyePoint Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|HAVN Life Sciences||0||0||0||0||N/A|
EyePoint Pharmaceuticals has a consensus price target of $33.00, suggesting a potential upside of 249.58%. Given EyePoint Pharmaceuticals’ higher possible upside, analysts plainly believe EyePoint Pharmaceuticals is more favorable than HAVN Life Sciences.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|HAVN Life Sciences||N/A||N/A||N/A||N/A||N/A|
|EyePoint Pharmaceuticals||$41.40 million||7.98||-$102.25 million||($2.82)||-3.35|
HAVN Life Sciences has higher earnings, but lower revenue than EyePoint Pharmaceuticals.
Insider & Institutional Ownership
99.4% of EyePoint Pharmaceuticals shares are held by institutional investors. 13.1% of EyePoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares HAVN Life Sciences and EyePoint Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|HAVN Life Sciences||N/A||N/A||N/A|
EyePoint Pharmaceuticals beats HAVN Life Sciences on 5 of the 8 factors compared between the two stocks.
About HAVN Life Sciences
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for HAVN Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HAVN Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.